No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki

The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Toriyama, Eo, Hata, Tomoko, Yokota, Ken‐ichi, Chiwata, Masahiko, Kamijo, Rena, Hashimoto, Miki, Taguchi, Masataka, Horai, Makiko, Matsuo, Masatoshi, Matsuo, Emi, Takasaki, Yumi, Kawaguchi, Yasuhisa, Itonaga, Hidehiro, Sato, Shinya, Ando, Koji, Sawayama, Yasushi, Taguchi, Jun, Imaizumi, Yoshitaka, Tsushima, Hideki, Jo, Tatsuro, Yoshida, Shinichiro, Moriuchi, Yukiyoshi, Miyazaki, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734160/
https://www.ncbi.nlm.nih.gov/pubmed/32939867
http://dx.doi.org/10.1111/cas.14653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734160/
https://www.ncbi.nlm.nih.gov/pubmed/32939867
http://dx.doi.org/10.1111/cas.14653

Ejemplares similares